Actively Recruiting

Early Phase 1
Age: 18Years - 70Years
All Genders
NCT07095075

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

Led by Nanjing Legend Biotech Co. · Updated on 2025-12-10

36

Participants Needed

5

Research Sites

219 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed/refractory autoimmune diseases.

CONDITIONS

Official Title

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary written informed consent provided
  • Age 18 to 70 years, any gender
  • Clinical laboratory values meet screening criteria
  • Positive test for CD19 and/or BCMA
  • For SLE: Meets at least 1 classification criteria for 6 months or more; positive for antinuclear antibody, anti-dsDNA antibody, or anti-Smith antibody; relapsed/refractory condition
  • For AAV: Meets 2022 ACR/EULAR classification criteria; positive for anti-MPO, p-ANCA, anti-PR3, or anti-MPO antibodies; relapsed/refractory condition
  • For SSc: Meets 2013 ACR/EULAR classification criteria; modified Rodnan skin score higher than 10; relapsed/refractory condition
  • For IIM: Meets 2017 EULAR/ACR criteria; positive for myositis-associated or specific antibodies; relapsed/refractory condition
  • For SjS: Meets 2016 ACR/EULAR diagnostic criteria; positive for anti-SSA and/or anti-SSB antibodies; relapsed/refractory condition
Not Eligible

You will not qualify if you...

  • Active infections such as hepatitis or tuberculosis
  • Presence of other autoimmune diseases
  • Serious underlying diseases including tumor or uncontrolled diabetes
  • Female subjects who are pregnant or breastfeeding
  • History of major organ transplantation
  • Prior receipt of any autologous cell therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

The Third The People's Hospital of BengBu

Bengbu, Anhui, China, 233000

Not Yet Recruiting

2

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

Hefei, Anhui, China, 230036

Actively Recruiting

3

Jiangsu Province Hospital

Nanjing, Jiangsu, China, 210029

Actively Recruiting

4

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China, 215006

Actively Recruiting

5

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China, 325015

Not Yet Recruiting

Loading map...

Research Team

W

Wenbo Hu

CONTACT

L

Liyuan Yu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases | DecenTrialz